The acute effects of a single session of intermittent hypoxia on blood biomarker concentrations and sleep parameters in people with Parkinson's disease: A randomized, double-blind, crossover trial.
Murilo Henrique Faria, Carlos Augusto Kalva-Filho, Vinicius Oliveira Queiroz et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized, double-blind, crossover trial examined acute and 24-hour effects of one intermittent hypoxia (IH) session on sleep and blood biomarkers in 15 people with Parkinson’s disease (pwPD) and 15 sex-matched healthy participants. Compared with normoxia, IH acutely reduced cortisol and leptin and increased adiponectin in pwPD; BDNF, IL-6, and iron did not change significantly. Sleep parameters showed no immediate post-session changes, although total sleep time in pwPD was lower at 24 hours than immediately after the session (p = 0.013).
Key findings
- In pwPD, IH acutely reduced cortisol and leptin and increased adiponectin; BDNF, IL-6, and iron showed no significant changes.
- No sleep-parameter changes were observed immediately after IH versus baseline in either group.
- In pwPD, total sleep time decreased 24 hours after IH versus the immediate post-session measurement (p = 0.013).
- IH reduced SpO₂ (5-20%) and produced a hypoxic dose nearly five times that of normoxia.
Why it matters
The findings suggest that a single controlled IH session can alter selected circulating biomarkers in pwPD without immediate measurable disruption to sleep behavior. The 24-hour reduction in total sleep time is also relevant when assessing delayed effects. These acute results provide a basis for further study but do not establish sustained physiological benefit or effects on Parkinson’s disease progression.
What to keep in mind
The study assessed only a single session and short-term outcomes in 15 people with Parkinson’s disease; it does not establish longer-term effects.